Episodios

  • Exploring Recent Developments in the Treatment of Prostate Cancer

    Exploring Recent Developments in the Treatment of Prostate Cancer
    Aug 8 2025
    Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.
    Más Menos
    39 m
  • Exploring Recent Developments in the Treatment of Prostate Cancer

    Exploring Recent Developments in the Treatment of Prostate Cancer
    Aug 6 2025
    Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.
    Más Menos
    31 m
  • B Cells as a Treatment Target in Myasthenia Gravis

    B Cells as a Treatment Target in Myasthenia Gravis
    Aug 4 2025
    Ali Habib, MD, and Arjun Seth, MD, discuss how B-cell–targeted therapies represent a promising upstream treatment approach for myasthenia gravis that could provide more sustained efficacy compared with current downstream treatments like complement inhibitors and FcRn antagonists, with CD19-targeting agents like inebilizumab showing particular promise in clinical trials for both acetylcholine receptor and MuSK antibody subtypes.
    Más Menos
    28 m
  • Advancing Pharmacist Engagement in Biliary Tract Cancer: Disease State and Treatment Considerations

    Advancing Pharmacist Engagement in Biliary Tract Cancer: Disease State and Treatment Considerations
    Jul 1 2025
    Courtney Cavalieri, PharmD, BCOP, and Kenneth Tham, PharmD, BCOP, discuss how pharmacists play a crucial role in managing biliary tract cancer patients by providing expertise on biomarker testing, treatment selection between targeted therapies like FGFR and HER2 inhibitors, developing monitoring protocols for unique toxicities such as hyperphosphatemia, and educating patients on side effect management to optimize treatment outcomes in this rare cancer type.
    Más Menos
    32 m
  • Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer

    Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
    Jun 5 2025
    Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic castration-resistant prostate cancer (nmCRPC) show darolutamide may offer superior tolerability with lower discontinuation rates and fewer drug interactions, while emphasizing the importance of critically evaluating real-world studies by examining methodology rather than just conclusions.
    Más Menos
    32 m
  • Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

    Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME
    May 28 2025
    Ehsan Rahimy, MD; David G. Miller, MD, Michael Klufas, MD, discusses how real-world treatment strategies for neovascular AMD and DME with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.
    Más Menos
    37 m
  • Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases

    Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases
    May 28 2025
    Ehsan Rahimy, MD; David G. Miller, MD, Esther Kim, MD, discusses how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases like AMD and DME, while highlighting the benefits of newer agents like aflibercept 8mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.
    Más Menos
    35 m
  • Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

    Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME
    May 28 2025
    Ehsan Rahimy, MD; David G. Miller, MD, Michael Klufas, MD, discusses how real-world treatment strategies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.
    Más Menos
    37 m